LABP
Landos Biopharma Inc (LABP)
$0.730.29%▲
Key Stats
$0.695
Day's Range
$0.7532
$0.5501
52-Week Range
$16.17
| Returns | |
| 1 month return | 6.95% |
| 3 month return | 49.58% |
| 1 year return | 93.17% |
| 5 year return | 94.03% |
Company Information
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma’s core expertise is in the development of therapeutic candidates targeting novel pathways at the interface of immunity and metabolism. Lead asset BT-11 is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes.
| Organization | Landos Biopharma Inc |
| CEO |
Analyst Recommendation
based on 13 analysts ratings
Buy
69%
Buy
30%
Hold
0%
Sell
Based on 13 Wall street analysts offering stock ratings for Landos Biopharma Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 872.22%Current
$0.72
Target
$7.0
Recommendation Trend
Based on 13 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 9 | 9 | 9 |
| Hold | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 42.7M |
| Book Value | 1.9 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0 |
| Earnings Share | -1.02 |
| Wall Street Target Price | 18.82 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Sales (ttm) | 2.37 |
| Price/Book (mrq) | 0.55 |
| Enterprise Value | -48612366 |
| Enterprise Value/Revenue | 0.67 |
| Enterprise Value/Ebitda | 1.26 |
Technicals
| 50 Day MA | 1.6 |
| 200 Day MA | 7.98 |
Institutional Holdings
Perceptive Advisors LLC
36.94%
RTW INVESTMENTS, LLC
10.62%
OUP Management Co., LLC
4.54%
BlackRock Inc
1.17%
Renaissance Technologies Corp
0.85%
JPMorgan Chase & Co
0.73%
